Compare Eli Lilly And Co (LLY) vs Zoom Video Communications, Inc. (ZM) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Zoom Communications (ZM) trades at $91.04, down 0.1% on the day, with a bullish technical signal from moving averages and support at $90. The company reported Q1 2026 EPS of $1.55, beating expectations, and maintains strong profitability with a net income margin of 42.0%. Recent news highlights AI product launches and a $1 billion buyback authorization, while analyst consensus price target sits at $118.79.

The outlook for ZM is cautiously optimistic, with upside potential driven by AI integration and solid cash flow, but risks include competitive pressure from Microsoft and Google, insider selling, and fluctuating cash flow trends. Wall Street sentiment is mixed, with 39% of analysts rating it Buy amid moderate growth projections.